

DILANTIN®

1. Product Name

Dilantin 30 mg and 100 mg phenytoin sodium capsules

Dilantin Infatabs 50 mg phenytoin chewable tablets

Dilantin 30 mg/5 mL phenytoin paediatric oral suspension

2. Qualitative and Quantitative Composition

Each 30 mg capsule contains 30 mg phenytoin sodium.

Each 100 mg capsule contains 100 mg phenytoin sodium.

Each 50 mg chewable infatabs contains 50 mg phenytoin.

Each 5 mL of paediatric suspension contains 30 mg phenytoin.

Excipients with known effect

All formulations contain sucrose.

The 30 mg capsule new formulation contains lactose monohydrate.

The 100 mg capsule (both new and old formulations) contains lactose monohydrate.

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

Capsules 30 mg: white, marked Parke Davis, P-D 30.

Capsules 100 mg: white / orange, marked Parke Davis and P-D 100.

Infatabs 50 mg: chewable tablets, spearmint-flavoured, for children, triangular, yellow, scored, marked P-D 007. The scoreline is not intended to divide the tablets into equal halves.

Paediatric suspension: reddish-pink suspension.

4. Clinical Particulars

4.1 Therapeutic indications

Dilantin is indicated for the control of generalised tonic-clonic (grand mal) and psychomotor seizures. Dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. Besides its effectiveness in controlling seizures, Dilantin frequently improves the mental condition

and outlook of epileptic patients and there is also increasing evidence that Dilantin is valuable in the prevention of seizures occurring during or after neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see section 4.2).

4.2 Dose and method of administration

Serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the free acid form.

Dilantin capsules (30 mg, 100 mg) are formulated with the sodium salt of phenytoin.

The free acid form of phenytoin is used in Dilantin Infatabs (50 mg) and Dilantin Paediatric Suspension (30 mg/5 mL).

Because there is approximately an 8% increase in drug content with the free form over that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt and vice versa.

Dose

Dosage should be individualised to obtain maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustments. Serum levels between 10 µg/mL and 20 µg/mL are considered to be clinically effective. With the recommended dosage, a period of at least 7 to 10 days may be required to achieve therapeutic blood levels of Dilantin, unless therapy is initiated with a loading dose. After the initial dose has been prescribed, plasma levels should be determined and the dosage adjusted if necessary to obtain a level in the therapeutic range; 10 µg/mL to 20 µg/mL (40 µmoles/L to 80 µmoles/L). Because phenytoin is hydroxylated in the liver by an enzyme system which is saturable, at high plasma levels small incremental doses may increase the half-life and produce very substantial increases in serum levels, when these are in the upper range.

Oral Administration

Although phenytoin has a relatively long plasma half-life, thrice daily dosing may reduce the incidence of gastric irritation since lower doses can be administered with thrice daily dosing as compared with twice daily dosing. Recent studies suggest that a better correlation is achieved between plasma levels and dose by expressing the latter on a body-weight basis.

Adult

Initiate therapy with 4 mg/kg/day to 5 mg/kg/day in 2 to 3 divided doses and assess plasma levels. A further upward dosage adjustment may be required to a maximum of 600 mg/day; dosage increments should be made at about 2 week intervals. Plasma phenytoin levels should be monitored should higher doses be required.

An initial dose of 6 mg/kg/day to 7 mg/kg/day would be more likely to ensure therapeutic levels, however, there is a risk that such a dose may achieve levels exceeding 20 µg/mL and increase the risk of toxicity.

Paediatric

Initiate therapy with 5 mg/kg/day in 2 to 3 equally divided doses not to exceed 300 mg daily. A recommended daily maintenance dosage is usually 4 mg/kg to 8 mg/kg. Children over 6 years may require the minimum adult dose (300 mg/day).

Paediatric dosage forms available include Dilantin Chewable Infatabs and Dilantin Paediatric Suspension.

Dilantin Paediatric Suspension is not for parenteral use.

Special populations

Elderly

Phenytoin clearance is decreased slightly in elderly patients and lower or less frequent dosing may be required (see section 4.4).

Renal or Hepatic Impairment

See section 4.4.

4.3 Contraindications

Patients with a history of hypersensitivity to phenytoin, or other hydantoin products, or the other ingredients in this product.

Co-administration of phenytoin with delavirdine is contraindicated due to the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

4.4 Special warnings and precautions for use

General

Phenytoin is not effective for absence (petit-mal) seizures. If generalised tonic-clonic (grand-mal) and absence (petit-mal) seizures are present, combined drug therapy is needed.

Phenytoin is not indicated for seizures due to hypoglycaemic or other metabolic causes. Appropriate diagnostic procedures should be performed as indicated.

Abrupt withdrawal of phenytoin in epileptic patients may precipitate status epilepticus, hence any need for dosage reduction, discontinuation, or substitution of alternative antiepileptic medication should be implemented gradually. However, in the event of an allergic or hypersensitivity reaction, rapid substitution of an alternative therapy may be necessary. In this case, alternative therapy should be an antiepileptic drug not belonging to the hydantoin chemical class.

In some individuals, the rate of phenytoin metabolism has been shown to be slower than normal. This slow rate of degradation may be due to enzymatic unavailability or to defective induction mechanisms, effects that appear to be genetically determined.

Acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.

Due to an increased fraction of unbound phenytoin in patients with renal or hepatic disease, or in those with hypoalbuminaemia, the interpretation of total phenytoin plasma concentrations should be made with caution. Unbound concentration of phenytoin may be elevated in patients with hyperbilirubinaemia. Unbound phenytoin concentrations may be more useful in these patient populations.

Suicidal Behaviour and Ideation

Antiepileptic drugs (AEDs), including phenytoin, increase the risk of suicidal thoughts or behaviour in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behaviour, and/or any unusual changes in mood or behaviour.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomised to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behaviour compared to patients randomised to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behaviour or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase

of approximately one case of suicidal thinking or behaviour for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behaviour with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behaviour beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behaviour was generally consistent among drugs in the data analysed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analysed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs.

Table 1. Risk by indication for antiepileptic drugs in the pooled analysis

Indication	Placebo Patients with Events Per 1000 Patients	Drug Patients with Events Per 1000 Patients	Relative Incidence of Events in Patients	Risk: Risk of Additional Drug Events Per 1000 Patients	Risk Difference: Drug with Patients
Epilepsy	1.0	3.4	3.5	2.4	
Psychiatric	5.7	8.5	1.5	2.9	
Other	1.0	1.8	1.9	0.9	
Total	2.4	4.3	1.8	1.9	

The relative risk for suicidal thoughts or behaviour was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing phenytoin or any other AED must balance this risk with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behaviour. Should suicidal thoughts and behaviour emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behaviour and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behaviour, or the emergence of suicidal thoughts, behaviour, or thoughts about self-harm. Behaviours of concern should be reported immediately to the treating doctor.

Cardiac Effects

Cases of bradycardia and asystole/cardiac arrest have been reported, most commonly in association with phenytoin toxicity (see section 4.9), but also at recommended phenytoin doses and levels.

Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms

Hypersensitivity syndrome (HSS) or drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in patients taking anticonvulsant drugs, including phenytoin. Some of these events have been fatal or life threatening.

HSS/DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, haematological abnormalities, myocarditis, myositis or pneumonitis. Initial symptoms may resemble an acute viral infection. Other common manifestations include arthralgias, jaundice, hepatomegaly, leucocytosis, and eosinophilia. The interval between the first drug exposure and symptoms is usually 2 to 4 weeks but has been reported in individuals receiving anticonvulsants for 3 or more months. If such signs and symptoms occur, the patient should be evaluated immediately. Phenytoin should be discontinued if an alternative aetiology for the signs and symptoms cannot be established and appropriate supportive measures provided.

Patients at higher risk for developing HSS/DRESS include black patients, patients who have experienced this syndrome in the past (with phenytoin or other anticonvulsant drugs), patients who have a family history of this syndrome and immunosuppressed patients. The syndrome is more severe in previously sensitised individuals.

Serious Dermatologic Reactions

Phenytoin can cause rare, severe cutaneous adverse reactions (SCARs) such as acute generalized exanthematous pustulosis (AGEP) (see section 4.8), exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS, which can be fatal. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, itching and other signs and symptoms of HSS/DRESS (see section 4.4), and should seek medical advice from their physician immediately when observing any indicative signs or symptoms. The physician should advise the patient to discontinue treatment if the rash appears. If the rash is of a milder type (measles-like or scarlatiniform), therapy may be resumed after the rash has completely disappeared. If the rash recurs upon reinstatement of therapy, further phenytoin medication is contraindicated. The risk of serious skin reactions and other hypersensitivity reactions to phenytoin, including skin rash, SJS, TEN, hepatotoxicity and HSS may be higher in black patients.

Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the human leucocyte antigen B (HLA-B) gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding use of drugs associated with SJS/TEN, including phenytoin, in HLA-B*1502 positive patients when alternative therapies are otherwise equally available.

Literature reports suggest that the combination of phenytoin, cranial irradiation and the gradual reduction of corticosteroids may be associated with the development of erythema multiforme, and/or SJS, and/or TEN.

Phenytoin and other hydantoin are contraindicated in patients who have experienced phenytoin hypersensitivity. Additionally caution should be exercised if using structurally similar compounds (e.g. barbiturates, succinimides, oxazolinediones and other related compounds) in these same patients.

Angioedema

Angioedema has been reported in patients treated with phenytoin. Phenytoin should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur (see section 4.8).

Hepatic Injury

The main site of biotransformation of phenytoin is the liver.

Toxic hepatitis and liver damage have been reported and may, in rare cases, be fatal.

Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These incidents usually occur within the first 2 months of treatment and may be associated with HSS/DRESS (see section 4.4). Patients with impaired liver function, elderly patients or those gravely ill, may show early signs of toxicity on standard dosage. Care should be exercised with dose adjustment in these patients.

The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin should be immediately discontinued and not re-administered.

The risk of hepatotoxicity and other hypersensitivity reactions to phenytoin may be higher in black patients.

Haematopoietic Effect

Haematopoietic complications, some fatal, have occasionally been reported in association with the administration of phenytoin. These have included thrombocytopenia, leucopenia, granulocytopenia, agranulocytosis and pancytopenia with or without bone marrow suppression.

There have been a number of reports suggesting a relationship between phenytoin and the development of lymphadenopathy (local or generalised) including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease. Although a cause-and-effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without signs and symptoms resembling HSS/DRESS (see section 4.4). In all cases of lymphadenopathy, follow-up observation for an extended period is indicated, and every effort should be made to achieve seizure control using alternative antiepileptic drugs.

While macrocytosis and megaloblastic anaemia have occurred, these conditions usually respond to folic acid therapy. If folic acid is added to phenytoin therapy, a decrease in seizure control may occur.

It is recommended that patients receiving long-term Dilantin therapy should undergo regular blood counts as serious haematological abnormalities have been reported (see section 4.8).

Metabolic Effect

In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this disease.

Hyperglycaemia, resulting from the drug's inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients.

Hypoalbuminaemia, from any cause, may be potentially toxic through its effect on increasing unbound phenytoin levels.

Musculoskeletal Effect

Phenytoin and other anticonvulsants that have been shown to induce the CYP450 enzyme are thought to affect bone mineral metabolism indirectly by increasing the metabolism of vitamin D3. This may lead to vitamin D deficiency and heightened risk of osteomalacia, bone fractures, osteoporosis, hypocalcaemia and hypophosphataemia in chronically treated epileptic patients.

Women of Childbearing Potential

Phenytoin may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse development outcomes (see section 4.6).

Phenytoin should not be used in women of childbearing potential unless the benefit is judged to outweigh the risks following careful consideration of alternative suitable treatment options. Before

the initiation of treatment with phenytoin in a woman of childbearing potential, pregnancy testing should be considered.

Women of childbearing potential should be fully informed of the potential risk to the fetus if they take phenytoin during pregnancy. Women of childbearing potential should be counselled regarding the need to consult their physician as soon as they are planning pregnancy to discuss switching to alternative treatments prior to conception and before contraception is discontinued (see section 4.6).

Women of childbearing potential should be counselled to contact their doctor immediately if they become pregnant or think they may be pregnant and are taking phenytoin.

Women of childbearing potential should use effective contraception during treatment and for one month after stopping treatment. Due to enzyme induction, phenytoin may result in a failure of the therapeutic effect of hormonal contraceptives, therefore, women of childbearing potential should be counselled regarding the use of other effective contraceptive methods (see sections 4.5 and 4.6).

Central Nervous System Effect

Serum levels of phenytoin sustained above the optimal range may produce confusional states referred to as delirium, psychosis or encephalopathy, or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, determination of plasma drug levels is recommended. Dose reduction of phenytoin therapy is indicated if plasma drug levels are excessive; if symptoms persist, termination of phenytoin therapy is recommended.

St John's Wort

Herbal preparations containing St John's wort (*Hypericum perforatum*) should not be used while taking phenytoin due to the risk of decreased plasma concentrations and reduced clinical effects of phenytoin.

Use in the Elderly

Phenytoin clearance tends to decrease with increasing age. Phenytoin dosing requirements are highly variable and must be individualised.

4.5 Interaction with other medicines and other forms of interaction

Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement. Phenytoin is metabolised by hepatic cytochrome (CYP) P450 enzymes CYP2C9 and CYP2C19 and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.

Phenytoin is a potent inducer of hepatic drug-metabolising enzymes and may reduce the levels of drugs metabolised by these enzymes.

There are many drugs that may increase or decrease phenytoin levels or that phenytoin may affect. These may result through an effect on metabolic degradation of phenytoin, interference with protein binding, alteration of absorption or by other mechanisms. Serum level determinations for phenytoin are especially helpful when possible drug interactions are suspected.

The most commonly occurring drug interactions are listed below:

Effects of Other Drugs on Phenytoin

Drugs That May Increase Phenytoin Serum Levels

Drug Classes	Drugs in each Class (such as)*
<i>Alcohol</i>	Alcohol (acute intake).

Drug Classes	Drugs in each Class (such as)*
<i>Analgesic / Anti-inflammatory agents</i>	Salicylates.
<i>Antibacterial agents</i>	Chloramphenicol, erythromycin, isoniazid, sulfadiazine, sulfamethoxazole-trimethoprim, sulfonamides.
<i>Anticonvulsants</i>	Oxcarbazepine, sodium valproate, succinimides (ethosuximide), topiramate.
<i>Antifungal agents</i>	Amphotericin B, fluconazole, itraconazole, ketoconazole, miconazole, voriconazole.
<i>Antineoplastic agents</i>	Capecitabine**, fluorouracil**.
<i>Antiplatelet agents</i>	Clopidogrel.
<i>Benzodiazepines / Psychotropic agents</i>	Diazepam, disulfiram, methylphenidate.
<i>Calcium channel blockers / Cardiovascular agents</i>	Amiodarone, diltiazem, nifedipine, ticlopidine.
<i>H2-antagonists</i>	Cimetidine.
<i>HMG-CoA reductase inhibitors</i>	Fluvastatin.
<i>Hormones</i>	Estrogens.
<i>Immunosuppressant drugs</i>	Tacrolimus.
<i>Oral hypoglycaemic agents</i>	Tolbutamide.
<i>Proton pump inhibitors</i>	Omeprazole.
<i>Serotonin re-uptake inhibitors</i>	Fluoxetine, fluvoxamine, sertraline.

* This list is not intended to be inclusive or comprehensive. Individual drug Data Sheet should be consulted.

** Increased phenytoin plasma concentrations have been reported during concomitant use of phenytoin with capecitabine or its metabolite fluorouracil (5FU). Formal interaction studies between phenytoin and capecitabine have not been conducted, but the mechanism of interaction is presumed to be inhibition of the CYP2C9 isoenzyme system by capecitabine. Patients taking phenytoin concomitantly with capecitabine or fluorouracil should be regularly monitored for increased phenytoin plasma levels.

Drugs That May Decrease Phenytoin Serum Levels

Drug Classes	Drugs in each Class (such as)*
<i>Alcohol</i>	Alcohol (chronic intake).
<i>Antibacterial agents / fluoroquinolones</i>	Ciprofloxacin, rifampicin.
<i>Anticonvulsants</i>	Vigabatrin.
<i>Antineoplastic agent</i>	Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate.
<i>Antiulcer agents</i>	Sucralfate.
<i>Antiretrovirals</i>	Fosamprenavir, nelfinavir**, ritonavir.
<i>Bronchodilators</i>	Theophylline.
<i>Folic acid</i>	Folic acid.
<i>Hyperglycaemic agents</i>	Diazoxide.
<i>St John's wort</i>	<i>Hypericum perforatum</i> (St John's wort).

* This list is not intended to be inclusive or comprehensive. Individual drug Data Sheet should be consulted.

** A pharmacokinetic interaction study between nelfinavir and phenytoin both administered orally showed that nelfinavir reduced AUC values of phenytoin (total) and free phenytoin by 29% and 28% respectively.

Therefore, phenytoin concentration should be monitored during co-administration with nelfinavir, as nelfinavir may reduce phenytoin plasma concentration.

Calcium ions may interfere with the absorption of phenytoin. Ingestion times of phenytoin and antacid preparations containing calcium should be staggered in patients with low serum phenytoin levels to prevent absorption problems.

Drugs That May Either Increase or Decrease Phenytoin Serum Levels

Drug Classes	Drugs in each Class (such as)*
<i>Antibacterial agents</i>	Ciprofloxacin
<i>Anticonvulsants**</i>	Carbamazepine, phenobarbital, sodium valproate [#] , valproic acid [#] .
<i>Antineoplastic agents</i>	Antineoplastic agents.
<i>Psychotropic agents</i>	Chlordiazepoxide, diazepam, phenothiazines.

* This list is not intended to be inclusive or comprehensive. Individual drug Data Sheet should be consulted.

** The effect of phenytoin on carbamazepine, phenobarbital, valproic acid and sodium valproate serum levels is unpredictable.

Sodium valproate and valproic acid are similar medications. The term valproate has been used to represent these medications.

Effect of Phenytoin on Other Drugs

The most common types of drugs whose serum levels and/or effects may be altered by phenytoin are listed below:

Drugs Whose Serum Levels and/or Effects May be Altered by Phenytoin

Drug Classes	Drugs in each Class (such as)*
<i>Antibacterial agents</i>	Doxycycline, rifampicin, tetracycline.
<i>Anticoagulants</i>	Warfarin, apixaban, dabigatran, edoxaban, rivaroxaban.
<i>Anticonvulsants</i>	Carbamazepine, lamotrigine, phenobarbital, sodium valproate [#] , valproic acid [#] , lacosamide.
<i>Antifungal agents</i>	Azoles, posaconazole, voriconazole.
<i>Anthelmintics</i>	Albendazole, praziquantel.
<i>Antineoplastic agents</i>	Teniposide.
<i>Antiplatelet agents</i>	Ticagrelor.
<i>Antiretrovirals</i>	Delavirdine, efavirenz, indinavir, lopinavir/ritonavir, ritonavir, saquinavir.
<i>Bronchodilators</i>	Theophylline.
<i>Calcium channel blockers / Cardiovascular agents</i>	Digitoxin, digoxin, disopyramide, mexiletine, nifedipine, nimodipine, quinidine, verapamil.
<i>Corticosteroids</i>	Corticosteroids.
<i>Ciclosporin</i>	Ciclosporin.
<i>Diuretics</i>	Furosemide.
<i>HMG-CoA reductase inhibitors</i>	Atorvastatin, fluvastatin, simvastatin.
<i>Hormones</i>	Estrogens, oral contraceptives (see section 4.4 and 4.6).
<i>Hyperglycaemic agents</i>	Diazoxide.

Drug Classes	Drugs in each Class (such as)*
<i>Immunosuppressant drugs</i>	Immunosuppressant drugs
<i>Neuromuscular blocking agents</i>	Alcuronium, pancuronium, rocuronium, vecuronium.
<i>Opioid analgesics</i>	Methadone.
<i>Oral hypoglycaemic agents</i>	Chlorpropamide, glibenclamide, tolbutamide.
<i>Psychotropic agents / Antidepressants</i>	Clozapine, paroxetine, quetiapine, sertraline.
<i>Vitamin D</i>	Vitamin D.
<i>Folic acid</i>	Folic acid.

* This list is not intended to be inclusive or comprehensive. Individual drug Data Sheet should be consulted.

Sodium valproate and valproic acid are similar medications. The term valproate has been used to represent these medications.

Hyperammonaemia with Concomitant Use of Valproate

Concomitant administration of phenytoin and valproate has been associated with an increased risk of valproate-associated hyperammonaemia. Patients treated concomitantly with these two drugs should be monitored for signs and symptoms of hyperammonaemia.

Seizure Threshold Lowering Drugs

Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and phenytoin dosage may need to be adjusted.

Drug-Enteral Feeding/Nutritional Preparations Interaction

Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected phenytoin serum levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation.

More frequent serum phenytoin level monitoring may be necessary in these patients.

Effects on Laboratory Tests

Phenytoin may cause decreased serum levels of protein bound iodine (PBI). It may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may cause raised serum levels of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT). Raised glucose levels appear to be due to inhibition of insulin secretion.

4.6 Fertility, pregnancy and lactation

Pregnancy

Category D

Phenytoin crosses the placenta in humans.

Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. In humans, phenytoin exposure during pregnancy is associated with a frequency of major malformations 2 to 3 times higher than that of the general population, which has a frequency of 2-3%. Malformations such as orofacial clefts, cardiac defects, craniofacial defects, nail and digit hypoplasia, and growth abnormalities (including microcephaly and prenatal growth deficiency), have been reported either individually or as part of a fetal Hydantoin Syndrome among children born to women with epilepsy who used phenytoin during pregnancy.

Neurodevelopmental disorder has been reported among children born to women with epilepsy who used phenytoin alone or in combination with other AEDs during pregnancy. Studies related to the

risk of neurodevelopmental disorders in children exposed to phenytoin during pregnancy are contradictory and a risk cannot be excluded.

Phenytoin should not be used during pregnancy unless the benefit is judged to outweigh the risks following careful consideration of alternative suitable treatment options. The woman should be fully informed of and understand the risks of taking phenytoin during pregnancy.

If based on a careful evaluation of the risks and the benefits, no alternative treatment option is suitable, and treatment with phenytoin is continued, the lowest effective dose of phenytoin should be used. If a woman is planning to become pregnant, all efforts should be made to switch to appropriate alternative treatment prior to conception and before contraception is discontinued. If a woman becomes pregnant while taking phenytoin, she should be referred to a specialist to reassess phenytoin treatment and consider alternative treatment options.

Mothers taking more than one anticonvulsant drug might have a higher risk of having a baby with a malformation than mothers taking one drug.

The reports suggesting a higher incidence of birth defects in children of drug-treated epileptic women cannot be regarded as adequate to prove a definite cause and effect relationship. There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans. Genetic factors or the epileptic condition itself may be more important than drug therapy in leading to birth defects. The great majority of mothers on anticonvulsant medication deliver normal infants.

It is important to note that antiepileptic drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures, because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo and fetus. The prescribing physician will wish to weigh these considerations in treating and counselling epileptic women of childbearing potential.

In addition to the reports of increased incidence of congenital malformations such as cleft lip/palate and heart malformations in children of women receiving phenytoin and other anticonvulsant drugs, there have been reports of a "fetal hydantoin syndrome". This consists of prenatal dysmorphic facial features, nail and digit hypoplasia, growth deficiency, (including microcephaly), and mental deficiency in children born to mothers who have received phenytoin.

There have been isolated reports of malignancies including neuroblastoma, in children whose mothers' received phenytoin during pregnancy.

.An increase in seizure frequency during pregnancy occurs in a high proportion of patients, because of altered phenytoin absorption or metabolism. Periodic measurement of serum phenytoin levels is particularly valuable in the management of a pregnant epileptic patient as a guide to an appropriate adjustment of dosage. However, postpartum restoration of the original dosage will probably be indicated. Neonatal coagulation defects have been reported within the first 24 hours in babies born to epileptic mothers receiving phenobarbital and / or phenytoin. Vitamin K1 has been shown to prevent or correct this defect and has been recommended to be given to the mother before delivery and the neonate after birth.

Women of childbearing potential

Phenytoin should not be used in women of childbearing potential unless the potential benefit is judged to outweigh the risks following careful consideration of alternative suitable treatment options. The woman should be fully informed of and understand the risk of potential harm to the fetus if phenytoin is taken during pregnancy and therefore the importance of planning any pregnancy. Pregnancy testing in women of childbearing potential should be considered prior to initiating treatment with phenytoin.

Women of childbearing potential should use effective contraception during treatment and for one month after stopping treatment. Due to enzyme induction, phenytoin may result in a failure of the therapeutic effect of hormonal contraceptives, therefore, women of childbearing potential should be counselled regarding the use of other effective contraceptive methods (see section 4.5). At least one effective method of contraception (such as an intra-uterine device) or two complementary forms of contraception including a barrier method should be used. Individual circumstances should be evaluated in each case, involving the patient in the discussion, when choosing the contraception method.

Breast-feeding

Breastfeeding is not recommended for women taking this drug because phenytoin appears to be secreted in low concentration in human milk. Phenytoin concentration in breast milk is approximately one-third of the corresponding maternal plasma concentration.

Fertility

No data available.

4.7 Effects on ability to drive and use machines

Patients should be advised not to drive a car or operate potentially dangerous machinery until it is known that this medication does not affect their ability to engage in these activities.

4.8 Undesirable effects

Gastrointestinal Disorders

Nausea, vomiting and constipation. To prevent gastric irritation due to alkalinity, Dilantin should be taken with at least half a glass of water. Gastric irritation may often be minimised by administering Dilantin during or following meals or by using Dilantin Suspension.

Gingival hyperplasia occurs frequently and its incidence may be reduced by good oral hygiene, including gum massage, frequent brushing and appropriate dental care.

Blood and Lymphatic System Disorders

Some fatal haematopoietic complications have occasionally been reported in association with the administration of phenytoin. Included in these are thrombocytopenia, leucopenia, granulocytopenia, agranulocytosis and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anaemia have occurred, these conditions usually respond to folic acid therapy.

Lymphadenopathy including benign lymph node hyperplasia, pseudolymphoma, lymphoma and Hodgkin's disease have been reported (see section 4.4).

Pure red cell aplasia has also been reported.

Nervous System Disorders

The most common manifestations encountered with phenytoin therapy are referable to this system and are usually dose-related. These include nystagmus, ataxia, slurred speech, decreased coordination, and mental confusion. Cerebellar atrophy has been reported and appears more likely in settings of elevated phenytoin levels and/or long-term phenytoin use (see section 4.4). Cases of dizziness, insomnia, transient nervousness, motor twitchings, headache, paraesthesia, somnolence, taste perversion and vertigo have also been reported.

There have also been rare reports of phenytoin induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those induced by phenothiazine and other neuroleptic drugs. A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy.

Antiepileptic drugs have been associated with an increased risk of suicidal behaviour, suicidal ideation and emergence or worsening of existing depression.

Immune System Disorders

Anaphylactoid reaction and anaphylaxis. HSS/DRESS (which may include, but is not limited to, symptoms such as arthralgias, eosinophilia, fever, liver dysfunction, lymphadenopathy or rash), systemic lupus erythematosus, periarteritis nodosa and immunoglobulin abnormalities (see section 4.4). Angioedema has been reported (see section 4.4).

Investigations

Thyroid function test abnormal.

Musculoskeletal and Connective Tissue Disorders

Bone fractures and osteomalacia have been associated with long-term (>10 years) use of phenytoin by patients with chronic epilepsy. Osteoporosis and other disorders of bone metabolism such as hypocalcaemia, hypophosphataemia and decreased serum levels of vitamin D metabolites have also been reported.

Dermatologic System

Dermatological manifestations sometimes associated with fever have included scarlatiniform or morbilliform rashes. The latter case is the most common with other types of dermatitis being more rare. In general, rashes are more frequent in children and young adults. More serious forms that may be fatal have also been reported and they include bullous, exfoliative, or other purpuric dermatitis, lupus erythematosus, AGEP, SJS, and TEN (see section 4.4). Urticaria has been reported.

Coarsening of the facial features, enlargement of the lips, hypertrichosis and hirsutism.

Hepatobiliary Disorders

Potentially fatal cases of acute hepatic failure, toxic hepatitis and liver damage may occur (see section 4.4). This effect may be the result of a hypersensitivity reaction.

Reproductive System and Breast Disorders

Peyronie's disease.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>.

4.9 Overdose

Signs and Symptoms

There are marked variations among individuals with respect to phenytoin plasma levels where toxicity may occur. Nystagmus or lateral gaze, usually appears at 20 µg/mL, ataxia at 30 µg/mL, dysarthria and lethargy appear when the plasma concentration is over 40 µg/mL, but as high a concentration as 50 µg/mL has been reported without evidence of toxicity. As much as 25 times the therapeutic dose has been taken to result in a serum concentration above 100 µg/mL with complete recovery. The lethal dose in children is not known. The lethal dose in adults is estimated to be 2 g to 5 g.

The cardinal initial symptoms are nystagmus, ataxia, dysarthria and CNS depression. Other signs that may be seen are tremor, hyperreflexia, somnolence, drowsiness, lethargy, hallucinations, confusion, mental status changes, slurred speech, blurred vision, nausea, vomiting, choreoathetosis, dyskinesias, hyperglycaemia and mild hypoglycaemia. Severe poisoning may result in respiratory

depression. Cardiotoxicity has not been reported with oral overdoses. Irreversible cerebellar dysfunction and atrophy have been reported as a delayed effect following severe overdoses. The patient may become comatose and hypotensive. Bradycardia and asystole/cardiac arrest have been reported (see section 4.4). Death is due to respiratory and circulatory depression.

Pharmacokinetic Information

In overdose settings, saturation of the hepatic hydroxylation system occurs and zero order kinetics predominate. Elimination follows a Michaelis-Menten model with a prolonged half-life. As phenytoin is continually excreted, elimination changes from zero order to first order kinetics and drug levels decrease more.

Serial plasma phenytoin concentrations should be monitored. In acute overdose, peak levels are frequently delayed for 24 to 48 hours, and occasionally as long as 7 days.

The proportion of phenytoin in plasma not bound to protein is an important measure of potential toxicity with free phenytoin levels of <1.5 µg/mL indicating no signs of toxicity; 1.5 µg/mL to 5 µg/mL seen with mild to moderate intoxication; and levels above 5 µg/mL associated with severe intoxication.

Treatment of Overdosage

Treatment is non-specific since there is no known antidote. Most cases of overdosage may be managed conservatively with symptomatic and supportive care. Signs and symptoms of toxicity may persist up to 7 to 10 days after ingestion.

Phenytoin is poorly absorbed in the stomach, therefore although routine use of activated charcoal is not recommended, it may be considered in the rare patient with a life threatening ingestion. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via a nasogastric tube, once the airway is protected. Administration of a further dose of activated charcoal may be considered in patients with rising serum phenytoin levels or worsening clinical condition despite initial decontamination.

Peritoneal dialysis, diuresis, haemodialysis, plasmapheresis, haemofiltration and total exchange transfusion may be of little benefit although the latter has been used in the treatment of severe intoxication in children.

In acute overdosage the possibility of other CNS depressants, including alcohol, should be borne in mind.

For further advice on management of overdose please contact the National Poisons Information Centre (0800 POISON or 0800 764 766).

5. Pharmacological Properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antiepileptic, ATC code: N03AB02

Dilantin is an anticonvulsant drug, which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex, where the spreading of seizure activity is inhibited. It is likely that, by promoting sodium efflux from neurones, Dilantin tends to stabilise the threshold against hyperexcitability caused by excessive stimulation or those environmental changes capable of reducing the gradient of sodium ions through membranes. This also applies to the reduction of post-tetanic potentiation at synapse level. Losing post-tetanic potential prevents the cortical seizure foci from deteriorating neighbouring cortical areas. In this sense, Dilantin reduces the maximal activity of brain stem centres associated with the tonic phase of generalised tonic-clonic (grand mal) seizures.

5.2 Pharmacokinetic properties

In general the reported plasma half-life of phenytoin averages 22 hours, with a range of 7 to 42 hours. Steady-state therapeutic levels are achieved at least 7 to 10 days (5 to 7 half-lives) after initiation of therapy with recommended doses of 300 mg/day.

Conventionally, with drugs following linear kinetics, the half-life is used to determine the dose rate, drug accumulation and the time to reach steady-state. Phenytoin, however, demonstrates non-linear kinetics and therefore the half-life is affected by the degree of absorption, saturation of metabolic pathways, dose and the degree of metabolic enzyme induction. This results in considerable inter- and intra- patient variability in phenytoin pharmacokinetics. As a consequence the clinical relevance of reported phenytoin half-life values are limited and cannot be used in the conventional manner to estimate the dosage regimen. When administering phenytoin to a patient it is necessary to measure serum levels as this provides the most accurate means of deriving a suitable dosage regimen.

Serum level determinations should originally be obtained at least 7 to 10 days after treatment initiation, dosage change, or addition or subtraction of another drug to the regimen so that equilibrium or steady-state will have been achieved. Further serum level determinations may be required to further refine the dosage regimen. Trough levels provide information about clinically effective serum level range and confirm patient compliance and are obtained just prior to the patient's next scheduled dose. Peak drug levels indicate an individual's threshold for emergence of dose-related side effects and are obtained at the time of expected peak concentration.

Optimum control without clinical signs of toxicity occurs more often with serum levels between 10 µg/mL and 20 µg/mL.

In most patients maintained at steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolisers of phenytoin.

Unusually high levels of phenytoin result from liver disease, congenital enzyme deficiency or drug interactions, which result in metabolic interference. Patients with large variations in phenytoin plasma levels, despite standard doses, present a difficult clinical problem. Serum level determinations in such patients may be particularly helpful. As phenytoin is highly protein bound, free phenytoin levels may be altered in patients whose protein binding characteristics differ from normal. Protein binding may be lower in neonates and hyperbilirubinaemic infants; also altered in patients with hypoalbuminaemia, uraemia or acute trauma and in pregnancy.

Most of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but more importantly by tubular secretion. Because phenytoin is hydroxylated in the liver by an enzyme system which is saturable at high plasma levels, small incremental doses may increase the half-life and produce very substantial increases in serum levels, when these levels are at or above the upper therapeutic range.

The steady-state level may be disproportionately increased, with resultant intoxication, from an increase in dosage of 10% or more.

Pharmacokinetic Interactions

Co-administration of nelfinavir tablets (1,250 mg twice a day) with phenytoin capsules (300 mg once a day) did not change the plasma concentration of nelfinavir. However, co-administration of nelfinavir reduced the AUC values of phenytoin (total) and free phenytoin by 29% and 28% respectively.

5.3 Preclinical safety data

None stated.

6. Pharmaceutical Particulars

6.1 *List of excipients*

Dilantin 30 mg capsules also contain:

- lactose monohydrate
- confectioner's sugar (sucrose with 3% maize starch)
- magnesium stearate
- purified talc
- titanium dioxide
- carbon black
- gelatin.

Note Dilantin 30 mg old formulation does not contain lactose monohydrate.

Dilantin 100 mg capsules also contain:

- lactose monohydrate
- confectioner's sugar (sucrose with 3% maize starch)
- purified talc
- magnesium stearate
- titanium dioxide
- sunset yellow FCF
- erythrosine
- carbon black
- gelatin.

Dilantin Infatabs also contains:

- sunset yellow FCF
- quinoline yellow
- saccharin sodium
- magnesium stearate
- purified talc
- confectioner's sugar (sucrose with 3% maize starch)
- spearmint flavour.

Dilantin Paediatric Suspension also contains:

- sodium benzoate
- sucrose
- glycerol
- aluminium magnesium silicate
- carmellose sodium
- polysorbate 40
- vanillin
- orange oil terpeneless
- ethanol
- carmoisine
- sunset yellow FCF
- citric acid monohydrate
- hydrochloric acid
- banana flavour
- purified water.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

Capsules 30 mg (old formulation): 3 years

Capsules 30 mg (new formulation): 2 years

Capsules 100 mg (old formulation): 1.5 years

Capsules 100 mg (new formulation): 2 years

Infatabs 50 mg: 3 years

Paediatric Suspension 30 mg/5 mL: 3 years

6.4 Special precautions for storage

Capsules: Store at or below 30°C.

Infatabs: Store at or below 30°C

Paediatric Suspension: Store at or below 25°C.

6.5 Nature and contents of container

Capsules: HDPE bottle with child-resistant polypropylene cap. Pack-size of 200 capsules (both 30 mg and 100 mg).

Infatabs: HDPE bottle with child-resistant polypropylene cap. Pack-size of 200 chewable tablets.

Paediatric Suspension: Amber glass bottle (Type III) with either an aluminium roll-on cap or white child-proof, tamper-evident polypropylene cap lined with Triseal (polyethylene) or Melinex (polyester) wad. Pack-size of 500 mL

Not all dosage forms, pack types and sizes may be marketed.

6.6 Special precautions for disposal and other handling

None stated

7. Medicines Schedule

Prescription Medicine

8. Sponsor Details

Viatrix Ltd
PO Box 11-183
Ellerslie
AUCKLAND
www.viatrix.co.nz
Telephone 0800 168 169

9. Date of First Approval

Dilantin capsules (30 mg and 100 mg): 31 December 1969

Dilantin Infatabs tablets (50 mg): 28 February 1975

Dilantin paediatric oral suspension (30 mg/5 mL): 31 December 1969

10. Date of Revision of the Text

04 May 2022

SUMMARY TABLE OF CHANGES

Section changed	Summary of new information
All	Minor editorial changes
4.4 & 4.6	Updates on use in women of childbearing potential
5.1	Pharmacotherapeutic group: antiepileptic, ATC code: N03AB02
10	New date of revision of text

DILANTIN® is a Viatris company trade mark